7 completed, 3 recruiting, 3 unknown, 3 withdrawn. 21 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 21 | Completed 7, Recruiting 3, Unknown 3, Withdrawn 3, Active not recruiting 2, Not yet recruiting 2, Terminated 1 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection Peginterferon alfa-2b, TDF, TAF - Hepatocellular Carcinoma, HEPATITIS B CHRONIC | Early Phase 1 | Not yet recruiting | Ningbo No.2 Hospital | 156 | 2026-03-31 | 2026-04-28 |
| An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B EPI-003 - Chronic Hepatitis B | Early Phase 1 | Not yet recruiting | Epigenic Therapeutics, Inc | 20 | 2024-12-20 | 2024-12-24 |
| Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus. - Hepatitis C, RDT | Early Phase 1 | Recruiting | Médecins du Monde | 3040 | 2024-10-03 | 2026-10-09 |
| Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion TVAX-008 - Chronic Hepatitis B | Early Phase 1 | Active not recruiting | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 20 | 2024-01-18 | 2025-10-02 |
| Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B PEGylated recombinant human interferon alpha-2b injection - Hepatitis B, Chronic | Early Phase 1 | Recruiting | Anhui Medical University | 1084 | 2023-07-01 | 2023-06-28 |
| The Efficacy and Safety of Rifaximin Treatment Rifaximin 200 mg, Standard Treatment without Rifaximin - Liver Failure, Acute on Chronic, Hepatic Encephalopathy | Early Phase 1 | Unknown | Sun Yat-sen University | 124 | 2023-03-09 | 2023-03-28 |
| A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF) - Hepatitis B, Chronic | Early Phase 1 | Withdrawn | Janssen Pharmaceutica N.V., Belgium | 2022-10-31 | 2025-06-25 | |
| Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera sofosbuvir and daclatasvir - Hepatitis C, Chronic | Early Phase 1 | Unknown | Assiut University | 40 | 2022-10-01 | 2022-07-26 |
| HA35 Moderate Alcoholic Hepatitis (AH) Study Sodium Hyaluronate, Placebo - Alcoholic Hepatitis | Early Phase 1 | Recruiting | The Cleveland Clinic | 54 | 2022-09-01 | 2026-09-24 |
| Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001) ChAdOx1 RVF - Rift Valley Fever | Early Phase 1 | Completed | University of Oxford | 15 | 2021-06-11 | 2023-05-19 |
| Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection Tenofovir Alafenamide 25 MG - Chronic Hepatitis B, Mother-to-child Block | Early Phase 1 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 50 | 2020-08-01 | 2020-12-22 |
| Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD Chronic Hepatitis B - Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease | Early Phase 1 | Completed | Sichuan Leshan Traditional Chinese Medicine Hospital | 92 | 2020-01-05 | 2022-08-31 |
| Hepatitis C Positive Donor Into Hepatitis C Negative Recipients Direct Acting Antivirals - Hepatitis C | Early Phase 1 | Withdrawn | University of Maryland, Baltimore | 2019-07-01 | 2023-05-06 | |
| Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease Erythropoietin - Autoimmune Hepatitis | Early Phase 1 | Completed | Northwestern University | 6 | 2019-01-25 | 2021-03-04 |
| Lung Transplant HCV, Pilot Study Sofosbuvir-velpatasvir (400 mg/100 mg), Ex Vivo Lung Perfusion (EVLP) - Lung Transplant Infection, Hepatitis C | Early Phase 1 | Active not recruiting | University Health Network, Toronto | 26 | 2017-09-19 | 2026-05-11 |
| Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients Direct acting Anti-Viral Therapy using Epclusa or Zepatier - Kidney Transplant, Hepatitis C | Early Phase 1 | Completed | Virginia Commonwealth University | 25 | 2017-08-17 | 2020-03-27 |
| Identification to Elimination in HCV-Infected Individuals OraQuick HCV Rapid Antibody Test - Hepatitis C | Early Phase 1 | Completed | TruCare Internal Medicine & Infectious Disease | 3051 | 2017-06-01 | 2020-07-02 |
| Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 GS-4997, Prednisolone, HepQuant SHUNT Test - Severe Alcoholic Hepatitis | Early Phase 1 | Withdrawn | HepQuant, LLC | 2016-07-31 | 2021-08-30 | |
| The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir - Chronic Hepatitis C | Early Phase 1 | Completed | Third Affiliated Hospital, Sun Yat-Sen University | 52 | 2016-02-01 | 2017-06-15 |
| Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis Ciprofloxacin, Placebo - Alcoholic Hepatitis, Alcoholic Cirrhosis | Early Phase 1 | Completed | University of Helsinki | 22 | 2015-04-01 | 2017-01-19 |
Showing 20 of 21. Sign in to see all of them.
Hepatitis B, Chronic (7) · Hepatitis C (5) · Hepatitis C, Chronic (3) · Hepatitis, Alcoholic (3) · Hepatitis B (2) · Acute-On-Chronic Liver Failure (1) · Camurati-Engelmann Syndrome (1) · Carcinoma, Hepatocellular (1) · Fibrosis (1) · Hepatic Encephalopathy (1) · Hepatitis, Autoimmune (1) · Liver Cirrhosis, Alcoholic (1) · Non-alcoholic Fatty Liver Disease (1) · Recurrence (1)
Digestive System Diseases (21) · Liver Diseases (21) · Infections (17) · Virus Diseases (17) · Blood-Borne Infections (16) · Communicable Diseases (16) · Hepatitis, Viral, Human (16) · Hepatitis, Chronic (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Chronic Disease (10) · Disease Attributes (10) · RNA Virus Infections (9) · DNA Virus Infections (8)
Sofosbuvir (2) · daclatasvir (2) · sofosbuvir-velpatasvir drug combination (2) · tenofovir alafenamide (2) · Betaine (1) · Ciprofloxacin (1) · Erythropoietin (1) · Hyaluronic Acid (1) · Prednisolone (1) · Ribavirin (1) · Rifaximin (1) · Tenofovir (1) · elbasvir-grazoprevir drug combination (1) · entecavir (1) · ledipasvir, sofosbuvir drug combination (1)
Third Affiliated Hospital, Sun Yat-Sen University (2) · Anhui Medical University (1) · Assiut University (1) · Epigenic Therapeutics, Inc (1) · Grand Theravac Life Sciences (Nanjing) Co., Ltd. (1) · HepQuant, LLC (1) · Janssen Pharmaceutica N.V., Belgium (1) · Médecins du Monde (1) · Ningbo No.2 Hospital (1) · Northwestern University (1) · Sichuan Leshan Traditional Chinese Medicine Hospital (1) · Sun Yat-sen University (1) · The Cleveland Clinic (1) · TruCare Internal Medicine & Infectious Disease (1) · University Health Network, Toronto (1)
China (7) · United States (7) · Armenia (1) · Canada (1) · Egypt (1) · Finland (1) · United Kingdom (1)
Adrian VS Hill, Prof (1) · Gaurav Gupta, MD (1) · Greg Everson, MD (1) · Jiabing Li, MD (1) · Marcelo Cypel, MD MSc FRCSC (1) · Margaret Hellard (1) · Mark E Mailliard, MD (1) · Perttu Sahlman, MD (1) · Qin Yang, MM (1) · Tuesdae R Stainbrook, DO, MPH (1) · Zhi-liang Gao, PhD (1)
PMID 10898704, PMID 20335583, PMID 21157444, PMID 23993913, PMID 25819304, PMID 26084406, PMID 27512927, PMID 28902040, PMID 28994123, PMID 31172417, PMID 31606437, PMID 31652392, PMID 31988585, PMID 32004593, PMID 32781201, PMID 33385299, PMID 33421158, PMID 33721837, PMID 34006193, PMID 35220659, PMID 36588741, PMID 37060917, PMID 41494657, PMID 41876153